Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & ...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & ...

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop - Assembly Biosciences (NASDAQ:ASMB)

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif., July 26, 2025 (GLOBE NE…

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall […] The post Assembly Biosciences Presents Data Highlightin…

Revolutionary Once-Monthly Herpes Treatment Could Replace Daily Pills, Phase 1 Data Reveals

Novel oral treatments show potential for weekly or monthly dosing, breaking away from daily regimens. Phase 1b results expected this fall. See latest clinical data.